I believe only in a trial.
Not up to date, but from what I've read, they've already established in trial that Abelacimab significantly reduces bleeds versus the NOAC it was tested against. However, the big question is if the stroke risk is also reduced. This will be tackled in future trials. Maybe someone has more update information. Very exciting development should things pan out.
Jim